deltatrials
Completed PHASE3 NCT00163137

Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone Loss

Double-Blind Placebo-Controlled Trial Of The Safety, Toleration and Efficacy Of Lasofoxifene 0.25 Mg/D and Raloxifene 60Mg/D For The Prevention Of Bone Loss In Postmenopausal Women

Sponsor: Ligand Pharmaceuticals

Conditions Osteoporosis
Interventions Placebo lasofoxifene raloxifene
Updated 6 times since 2017 Last updated: Aug 10, 2011 Started: May 31, 2003 Primary completion: Oct 31, 2005 Completion: Oct 31, 2005

This PHASE3 trial investigates Osteoporosis and is currently completed. Ligand Pharmaceuticals leads this study, which shows 6 recorded versions since 2003 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

May 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Ligand Pharmaceuticals
Data source: Ligand Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States, Albany, United States, Albuquerque, United States, American Fork, United States, Arden Hills, United States, Atlanta, United States, Berkeley, United States, Bethesda, United States, Brandon, United States, Chattanooga, United States and 41 more location s